Article info

Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study

Authors

  1. Correspondence to Dr Philip J Mease, Rheumatology Research, Swedish Medical Center, Seattle, Washington, USA; pmease{at}philipmease.com
View Full Text

Citation

Mease PJ, Chohan S, Fructuoso FJG, et al
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study

Publication history

  • Received August 31, 2020
  • Revised January 29, 2021
  • Accepted February 1, 2021
  • First published May 13, 2021.
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.